Home › Posts tagged Pembrolizumab [Keytruda]
Blog Archives

Cancer therapies: Immune checkpoint inhibitors may kill you

Posted on by by Posted in Adverse Drug Reaction [ADR], New Research, New Safety Information, Thasso Post, Theragenomic Medicine No Comments ↓

…

Read more ›

Tags: , , , , , , , , , , , , , , , , , ,

Pembrolizumab (Keytruda): Clinical trials on hold

Posted on by by Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

September 2, 2017 – The American Food & Drug Administration (FDA) has announced that two clinical trials with Pembrolizumab (Keytruda) in patients with multiple myeloma have been put on hold. The FDA informs the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Pembrolizumab (Keytruda) in combination with dexamethasone and an immunomodulatory agent (Lenalidomide (Revlimid) or Pomalidomide (Pomalyst)) for the treatment of patients with multiple myeloma.

…

Read more ›

Tags: , , , , , , , , , , ,

Biomarker-guided Larotrectinib for all cancer types?

Posted on by by Posted in Genetic Background, Genetic Predisposition, New Research, On The Horizon, Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

June 09, 2017 –  It’s only a couple of days that the American Food & Drug Administration (FDA) approved for the first time a cancer treatment for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying a specific genetic feature (i.e.,

…

Read more ›

Tags: , , , , , , , , , ,

First cancer treatment for any solid tumor with MSI-H or dMMR approved

Posted on by by Posted in Genetic Background, New Indication Approval, Personalized Medicine, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓
May 24, 2917 – The American Food & Drug Administration (FDA) just approved a major extension of the clinical indications for Pembrolizumab (Keytruda). For the first time,  a cancer treatment has been approved for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying a specific genetic feature (i.e.,

…

Read more ›

Tags: , , , , , , , , ,

Risk of severe if not fatal skin reactions with Pembrolizumab (Keytruda)

Posted on by by Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

March 21, 2017 – Health Canada just communicated this important safety information: Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) under treatment of patients with Pembrolizumab (Keytruda) have been reported internationally in the clinical trials and post-marketing setting.

…

Read more ›

Tags: , , , , , ,

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Posted on by by Posted in Genetic Background, New Research, On The Horizon, Thasso Post, Theragenomic Medicine No Comments ↓

September 06, 2016 – Genetic mutations associated with acquired resistance to PD-1 blockade in melanoma have been suspected to be involved in the clinical observation that while approximately 75% of objective responses to anti–programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years,

…

Read more ›

Tags: , , , , , , , , , ,

Pembrolizumab [Keytruda] for advanced melanoma: First PD-1 blocking drug to receive approval

Posted on by by Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments ↓

September 11, 2014 – The U.S. Food and Drug Administration today granted accelerated approval to Pembrolizumab (Keytruda) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.

Melanoma, which accounts for approximately 5 percent of all new cancers in the United States,

…

Read more ›

Tags: , , , ,

thasso: donate

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

RSS random genetics

  • Distinct social profile and high ASD risk, 3q29 deletion survey finds July 19, 2019
    A survey of 93 people with 3q29 deletion syndrome reveals a distinct pattern of social disability and anxiety, even without a diagnosis of autism spectrum disorder. The results were published online in Molecular Autism on July 16.
  • Study sheds light on the darker parts of our genetic heritage July 19, 2019
    More than half of our genome consists of transposons,DNA sequences that are reminiscent of ancient, extinct viruses.Transposons are normally silenced by a process known as DNA methylation, but their activation can lead to serious diseases. Very little is known about transposons but researchers in an international collaboration project have now succeeded for the first time […]
  • Molecular cause for severe multi-organ syndrome July 19, 2019
    Three unrelated families on three continents (from continental Portugal, the United States and Brazil), all with healthy ancestors, had children with a very rare multi-organ condition that causes early-onset retinal degeneration, sensorineural hearing loss, microcephaly, intellectual disability, and skeletal dysplasia with scoliosis and short stature.
  • Researchers determine epigenetic origin of docetaxel-resistant breast cancer July 19, 2019
    Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have published a study in Molecular Cancer Research in which they identify methylation patterns associated with different subtypes of breast cancer, and a subclassification of the group of "triple negatives," a breast cancer type typically associated with poor prognosis. In addition, they identified changes in DNA methylation […]
  • Researchers report the function of reverse-twisting DNA July 19, 2019
    Normally, the two strands of the DNA double helix wind around each other in a right-handed spiral. However, there is another conformation called Z-DNA in which the strands twist to the left. The function of Z-DNA has remained a mystery since its discovery. A newly published paper unambiguously establishes that the Z-conformation is key to […]

RSS random science

  • Study sheds light on the darker parts of our genetic heritage July 19, 2019
    More than half of our genome consists of transposons, DNA sequences that are reminiscent of ancient, extinct viruses. Transposons are normally silenced by a process known as DNA methylation, but their activation can lead to serious diseases. Very little is known about transposons but researchers in an international collaboration project have now succeeded for the first time […]
  • Flexible user interface distribution for ubiquitous multi-device interaction July 19, 2019
    KAIST researchers have developed mobile software platform technology that allows a mobile application (app) to be executed simultaneously and more dynamically on multiple smart devices. Its high flexibility and broad applicability can help accelerate a shift from the current single-device paradigm to a multiple one, which enables users to utilize mobile apps in ways previously […]
  • Atomically precise models improve understanding of fuel cells July 19, 2019
    Simulations from researchers in Japan provide new insights into the reactions occurring in solid-oxide fuel cells by using realistic atomic-scale models of the electrode active site based on microscope observations instead of the simplified and idealized atomic structures employed in previous studies. This better understanding of how the structures in the cells affect the reactions […]
  • Predicting long-term risk of death from chest X-rays July 19, 2019
    Researchers in this study looked at whether a computing system that analyzed data from thousands of chest X-rays of smokers and nonsmokers and developed a risk score could predict long-term risk of death.
  • Ivacaftor may reduce common infections in patients with CF July 19, 2019
    Patients with cystic fibrosis who take ivacaftor appear to have fewer respiratory infections over time than those not taking the drug, according to new research published online in the Annals of the American Thoracic Society.
Top